Stocks and Investing
Stocks and Investing
Tue, January 31, 2023
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Bradley Canino Initiated (SNDX) at Strong Buy and Held Target at $37 on, Jan 31st, 2023
Bradley Canino of Stifel, Initiated "Syndax Pharmaceuticals, Inc." (SNDX) at Strong Buy and Held Target at $37 on, Jan 31st, 2023.
Bradley has made no other calls on SNDX in the last 4 months.
There are 3 other peers that have a rating on SNDX. Out of the 3 peers that are also analyzing SNDX, 0 agree with Bradley's Rating of Hold.
These are the ratings of the 3 analyists that currently disagree with Bradley
- Anupam Rama of "JP Morgan" Initiated at Buy and Held Target at $41 on, Tuesday, January 3rd, 2023
- Edward White of "HC Wainwright & Co." Maintained at Strong Buy with Increased Target to $33 on, Monday, December 12th, 2022
- Madhu Kumar of "Goldman Sachs" Maintained at Strong Buy with Increased Target to $39 on, Monday, December 12th, 2022
Contributing Sources